KHN’s ‘What the Health?’: Our 200th Episode!
The federal approval of a controversial drug to treat Alzheimer’s disease has reignited the debate over drug prices and the way the Food and Drug Administration makes decisions. Meanwhile, President Joe Biden seeks to gain goodwill overseas as he announces the U.S. will provide 500 million doses of covid vaccine to international health efforts. Sarah Karlin-Smith of the Pink Sheet, Margot Sanger-Katz of The New York Times and Joanne Kenen of Politico join KHN’s Julie Rovner to discuss these issues and more. Also, Rovner interviews Chiquita Brooks-LaSure, the new administrator of the Centers for Medicare & Medicaid Services. And to mark the podcast’s 200th episode, the panelists discuss what has surprised them most and least over the past four years.
KHN’s ‘What the Health?’: The Drug Price Dilemma
Republicans, Democrats and the public at large agree that prices for prescription drugs are too high. But no one seems to know how to fix it. Vanderbilt University drug price researcher Stacie Dusetzina explains the basics of why drugs cost so much and why it’s hard to do something about it. Joanne Kenen of Politico, Sarah Karlin-Smith of the Pink Sheet and Anna Edney of Bloomberg News join KHN’s Julie Rovner to discuss the prospects for policy changes.
Readers and Tweeters React to Racism, Inequities in Health Care
Kaiser Health News gives readers a chance to comment on a recent batch of stories.
KHN Journalist Combs for Clues on Covid’s Origins
KHN and California Healthline staff made the rounds on national and local media this week to discuss their stories. Here’s a collection of their appearances.
KHN’s ‘What the Health?’: The Return of the Public Option
Lawmakers are working on fleshing out the concept of a “public option,” a government-run or heavily regulated insurance plan that would compete with private insurance. But the details are complicated, both substantively and politically. Meanwhile, bioethicists are debating whether the U.S. should be vaccinating low-risk adolescents against covid-19 while high-risk adults in other countries are still waiting. Margot Sanger-Katz of The New York Times, Alice Miranda Ollstein of Politico and Rachana Pradhan of KHN join KHN’s Julie Rovner to discuss these issues and more. Plus, for extra credit, the panelists recommend their favorite health policy stories of the week they think you should read, too.
Watch: Elisabeth Rosenthal on the Covid-19 ‘Infodemic’ and the Media
The journalists talked about how the nation’s political divides made some people realize they could spread misinformation for political or financial gain.
Listen: A Podcast Explores Controversial Efforts to Waive Drugmakers’ Vaccine Patent Rights
KHN’s Julie Rovner joins The Atlantic’s “Social Distance” podcast, hosted by Dr. James Hamblin and Maeve Higgins, to talk about President Joe Biden’s support for an initiative to waive patent protection for covid vaccines and the politics of drug policy in the United States.
From Covid Coverage to ‘Public Option’ Plans, Journalists Delve Into Details
KHN and California Healthline staff made the rounds on national and local media this week to discuss their stories. Here’s a collection of their appearances.
KHN’s ‘What the Health?’: Sharing Vaccines With the World
The Biden administration is bucking the drug industry and backing a waiver of covid-19 vaccine patent protections to help the rest of the world vaccinate its populations. Here at home, the Food and Drug Administration wants to ban menthol flavorings for cigarettes, setting off a fight with the tobacco industry. Alice Miranda Ollstein of Politico, Tami Luhby of CNN and Kimberly Leonard of Business Insider join KHN’s Julie Rovner to discuss these issues and more. Plus, for extra credit, the panelists recommend their favorite health policy stories of the week they think you should read, too.
Journalists Track Biden’s First 100 Days
KHN and California Healthline staff made the rounds on national and local media this week to discuss their stories. Here’s a collection of their appearances.